KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Staar Surgical (STAA) Assets (2016 - 2026)

Staar Surgical's Assets history spans 17 years, with the latest figure at $451.7 million for Q1 2026.

  • For Q1 2026, Assets fell 11.35% year-over-year to $451.7 million; the TTM value through Jan 2026 reached $451.7 million, down 11.35%, while the annual FY2026 figure was $451.7 million, 11.35% down from the prior year.
  • Assets reached $451.7 million in Q1 2026 per STAA's latest filing, down from $456.4 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $537.6 million in Q3 2024 to a low of $351.2 million in Q2 2022.
  • Average Assets over 5 years is $451.0 million, with a median of $454.0 million recorded in 2025.
  • Peak YoY movement for Assets: soared 32.12% in 2022, then decreased 15.11% in 2025.
  • A 5-year view of Assets shows it stood at $418.8 million in 2022, then grew by 16.68% to $488.7 million in 2023, then grew by 4.26% to $509.5 million in 2024, then fell by 10.43% to $456.4 million in 2025, then dropped by 1.03% to $451.7 million in 2026.
  • Per Business Quant, the three most recent readings for STAA's Assets are $451.7 million (Q1 2026), $456.4 million (Q3 2025), and $437.8 million (Q2 2025).